Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Transposon Therapeutics, Inc. is active in the Biotechnology & Pharmaceuticals technology area with 1 pending office action currently in its portfolio. This prosecution is overseen by 1 distinct examiner, CRAIGO, BAHAR ALAWI. As the busiest examiner for the company, CRAIGO, BAHAR ALAWI is responsible for the 1 pending office action. The company's current filings are located within 1 distinct art unit.
The focus on 1 distinct art unit suggests a specific technical niche within the biotechnology sector. Because there is only 1 distinct examiner and 1 pending office action, the company's immediate patent goals are concentrated on a single examination process. Practitioners can observe that the relationship with CRAIGO, BAHAR ALAWI is the central factor in the company's current prosecution landscape. This lack of examiner or art unit diversity indicates a streamlined approach where the success of the 1 pending office action is the primary objective for the company's intellectual property management.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CRAIGO, BAHAR ALAWI | 1 | 47.1% | +27.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18566413 | LINE-1 INHIBITORS AS COGNITIVE ENHANCERS | CRAIGO, BAHAR ALAWI | — |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18566413 | LINE-1 INHIBITORS AS COGNITIVE ENHANCERS | CRAIGO, BAHAR ALAWI | 1699 | §102§112DP | Non-Final OA | — | Pending | Dec 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial